Clinical Trial Update: Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Polatuzumab Vedotin in combination with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for relapsed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Fudan University | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING